KalVista Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '25 Jul 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Revenue	1.43	-	-	-	-	-
Cost of Revenue	60.85	71.71	86.17	80.28	70.17	41.29
Gross Profit	-59.42	-71.71	-86.17	-80.28	-70.17	-41.29
Selling, General & Admin	143.37	116.29	54.28	30.6	26.45	16.64
Operating Expenses	143.37	116.29	54.28	30.6	26.45	16.64
Operating Income	-202.79	-188	-140.45	-110.87	-96.61	-57.92
Interest Expense	-9.31	-5.79	-	-	-	-
Interest & Investment Income	6.59	6.44	3.9	2.23	1.09	0.9
Currency Exchange Gain (Loss)	3.89	2.48	0.14	0.09	-1.54	0.85
Other Non Operating Income (Expenses)	2.23	3.25	8.44	15.78	15.3	9.93
EBT Excluding Unusual Items	-199.38	-181.61	-127.97	-92.77	-81.76	-46.24
Gain (Loss) on Sale of Investments	1.83	1.56	1.33	-0.14	-0.58	-
Pretax Income	-197.55	-180.05	-126.64	-92.91	-82.34	-46.24
Income Tax Expense	5.55	3.39	-	-	-	-
Net Income	-203.1	-183.44	-126.64	-92.91	-82.34	-46.24
Net Income to Common	-203.1	-183.44	-126.64	-92.91	-82.34	-46.24
Shares Outstanding (Basic)	51	50	37	28	24	19
Shares Outstanding (Diluted)	51	50	37	28	24	19
Shares Change (YoY)	29.51%	34.98%	31.89%	13.96%	28.17%	7.58%
EPS (Basic)	-3.95	-3.69	-3.44	-3.33	-3.36	-2.42
EPS (Diluted)	-3.95	-3.69	-3.44	-3.33	-3.36	-2.42
Free Cash Flow	-167.89	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-3.26	-3.09	-2.43	-2.74	-3.23	-1.58
Operating Margin	-14220.83%	-	-	-	-	-
Profit Margin	-14242.43%	-	-	-	-	-
Free Cash Flow Margin	-11773.63%	-	-	-	-	-
EBITDA	-201.82	-187.05	-139.63	-110.15	-96.05	-57.39
D&A For EBITDA	0.97	0.94	0.82	0.72	0.56	0.54
EBIT	-202.79	-188	-140.45	-110.87	-96.61	-57.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.